Dr Xin Liu
Dr

Xin Liu

Email: 
Phone: 
+61 7 344 38031

Background

Dr Liu is a research fellow with more than 15 years of experience in the field of pharmacometrics. She specialises in population pharmacokinetic modelling and provides popPK analysis and dosing simulation support for various projects in Centre of Research Excellence RESPOND

Availability

Dr Xin Liu is:
Available for supervision

Fields of research

Clinical sciences Pharmacology and pharmaceutical sciences

Qualifications

  • Doctor of Philosophy, National University of Singapore

Search Professor Xin Liu’s works on UQ eSpace

95 works between 2003 and 2025
All (95) Journal Article (78) Book Chapter (4) Conference Publication (13)

81 - 95 of 95 works

2010

Journal Article

Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts

He, S., Liu, X., Yang, Y., Huang, W., Xu, S., Yang, S., Zhang, X. and Roberts, M. S. (2010). Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. British Journal of Dermatology, 162 (3), 538-546. doi: 10.1111/j.1365-2133.2009.09511.x

Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts

2010

Journal Article

Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2

Liu, Xin, Yang, Yan, Zhang, Xiaoxiang, Xu, Shengxin, He, Shufang, Huang, Weijuan and Roberts, Michael S. (2010). Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2. Journal of Gastroenterology and Hepatology, 25 (2), 420-426. doi: 10.1111/j.1440-1746.2009.05981.x

Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2

2010

Conference Publication

Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients

Roberts, D. M., Roberts, M. S., Liu, X., Roberts, J. A., Lipman, J. and Bellomo, R. (2010). Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients. ESICM 2010: 23rd Annual Meeting of the European Society of Intensive Care Medicine, Barcelona, Spain, 9-13 October, 2010. Heidelberg, Germany: Springer. doi: 10.1007/s00134-010-1999-x

Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients

2010

Conference Publication

Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients

Roberts, D., Roberts, M., Liu, X., Roberts, J., Lipman, J. and Bellomo, R. (2010). Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients. ANZSN 2010: 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth, WA, Australia, 12-15 September 2010. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2010.01377_1.x

Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients

2010

Journal Article

Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model

Zou, Yu-Hong, Liu, Xin, Khlentzos, Alexander M., Asadian, Peyman, Li, Peng, Thorling, Camilla A., Robertson, Thomas A., Fletcher, Linda M., Crawford, Darrell H. G. and Roberts, Michael S. (2010). Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model. Drug Metabolism and Pharmacokinetics, 25 (5), 442-449. doi: 10.2133/dmpk.DMPK-10-RG-031

Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model

2009

Journal Article

Influence of perfusate composition on drug disposition in the in-situ perfused rat lung

Liu, X., Wang, J. Y., Khlentzos, A. M., Fontaine, F., Nikolovski, J., Goh, L.- A. and Roberts, M. S. (2009). Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. International Journal of Pharmaceutics, 382 (1-2), 192-197. doi: 10.1016/j.ijpharm.2009.08.028

Influence of perfusate composition on drug disposition in the in-situ perfused rat lung

2009

Book Chapter

Optimizing drug dosing in the ICU

Kruger, P., Liu, X. and Roberts, M. S. (2009). Optimizing drug dosing in the ICU. Optimizing Drug Dosing in the ICU. (pp. 859-869) edited by Vincent, JL. Berlin, Germany: Springer. doi: 10.1007/978-3-540-92276-6

Optimizing drug dosing in the ICU

2008

Journal Article

Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.

Liu, Xin, Chan, S. Y. and Ho, P. C. (2008). Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.. Cancer Chemotherapy and Pharmacology, 63 (1), 167-174. doi: 10.1007/s00280-008-0763-1

Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.

2008

Journal Article

The prediction of the hepatic clearance of Tanshinone IIA in a rat liver subcellular fractions: accuracy improvement

Li, P., Wang, G-J., Li, J., Liu, X., Khlentzos, A. and Roberts, M. S. (2008). The prediction of the hepatic clearance of Tanshinone IIA in a rat liver subcellular fractions: accuracy improvement. Current Drug Metabolism, 9 (1), 39-45. doi: 10.2174/138920008783331103

The prediction of the hepatic clearance of Tanshinone IIA in a rat liver subcellular fractions: accuracy improvement

2007

Journal Article

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species

Venkadesh, Pilla Reddy, Goh, Evelyn, Zeng, Peizi, New, Lee Sun, Liu, Xin, Pasha, Mohammed Khalid, Sangthongpitag, Kanda, Yeo, Pauline and Kantharaj, Ethirajulu (2007). In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species. Biological and Pharmaceutical Bulletin, 30 (5), 1021-1024. doi: 10.1248/bpb.30.1021

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species

2007

Journal Article

Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies

Yeo, Pauline, Xin, Liu, Goh, Evelyn, New, Lee Sun, Zeng, Peizi, Wu, Xiaofeng, Venkatesh, P. and Kantharaj, Ethirajulu (2007). Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies. Biomedical Chromatography, 21 (2), 184-189. doi: 10.1002/bmc.734

Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies

2006

Conference Publication

ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor

Sangthongpitag, K., Wang, H., Yeo, P., Liu, X., Goh, E., New, L., Zeng, P., Wu, X., Hu, C. and Ethirajulu, K. (2006). ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(06)70172-0

ADME and PK/PD attributes of SB939, a potent orally active HDAC inhibitor

2005

Journal Article

Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis

Yap, K. L., Liu, X., Thenmozhiyal, J. C. and Ho, P. C. (2005). Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. European Journal of Pharmaceutical Sciences, 25 (1), 49-56. doi: 10.1016/j.ejps.2005.01.021

Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis

2004

Journal Article

Biopharmaceutics of beta-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley rats

Liu, X., Lin, H. S., Chan, S. Y. and Ho, P. C. (2004). Biopharmaceutics of beta-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley rats. Journal of Pharmaceutical Sciences, 93 (4), 805-815. doi: 10.1002/jps.10578

Biopharmaceutics of beta-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley rats

2003

Journal Article

Inclusion of acitretin into cyclodextrins: Phase solubility, photostability, and physicochemical characterization

Liu, X., Lin, H. S., Thenmozhiyal, J. C., Chan, S. Y. and Ho, P. C. (2003). Inclusion of acitretin into cyclodextrins: Phase solubility, photostability, and physicochemical characterization. Journal of Pharmaceutical Sciences, 92 (12), 2449-2457. doi: 10.1002/jps.10495

Inclusion of acitretin into cyclodextrins: Phase solubility, photostability, and physicochemical characterization

Current funding

  • 2025 - 2026
    Quality Medication Care Research UQ Centre for Clinical Research
    Quality Medication Care Pty Ltd
    Open grant

Past funding

  • 2021
    A novel CD14-targeting approach for the treatment of primary sclerosing cholangitis
    Ferguson Foundation (Reginald Ferguson)
    Open grant
  • 2020 - 2021
    Mechanistic and comparative toxicity of commercial essential oils
    Agrifutures Australia
    Open grant
  • 2018 - 2021
    Formulation drug product quality attributes in dermal physiologically-based pharmacokinetic models for topical dermatological drug products and transdermal delivery systems
    United States Food and Drug Administration
    Open grant
  • 2018 - 2021
    Improving oesophageal adenocarcinoma outcomes through understanding genomics and treatment toxicity (NHMRC Project Grant led by The Council of the Queensland Institute of Medical Research)
    Queensland Institute of Medical Research
    Open grant
  • 2017 - 2018
    Dr Xin Liu - Maternity Funding (Advance Queensland Women's Academic Fund)
    Queensland Government Advance Queensland Women's Academic Fund
    Open grant
  • 2017 - 2018
    Optimising the N-acetylcysteine dose regimen for managing paracetamol overdose using mechanistic biomarkers (TACT Pilot Grant awarded under NHMRC Program Grant APP1055176 administered by Uni Sydney)
    University of Sydney
    Open grant
  • 2017 - 2021
    Physiologically-based pharmacokinetics and pharmacodynamics of therapeutic stem cells for liver disease
    NHMRC Project Grant
    Open grant
  • 2016 - 2017
    Optimizing the Treatment of Paracetamol Toxicity by Mechanistic Modelling Based on Advanced Imaging - Toxicology (TACT Pilot grant awarded under NHMRC Program grant APP1055176 admin by Uni of Syd)
    University of Sydney
    Open grant

Availability

Dr Xin Liu is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Dr Xin Liu's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au